Avivo BioOptics

Avivo BioOptics’ (ABO) is optimizing the cancer screening process with its InPoint? System – the first 10min, POC, CLIA-waived, early-stage cancer risk assessment – improving testing compliance and enhancing clinical outcomes by conveniently monitoring average risk patients annually to identify high-risk patients needing follow-on stardard-of-care. The first application for use is Colorectal cancer (CRC). The InPoint? System assesses a patient’s risk of developing cancer. InPoint's underlying Low-coherence Enhanced Backscatter (LEBS) technology is an optical platform that examines and analyzes nanoscopic structural tissue changes. The technology is based on the concept of field carcinogenesis – during the initial stages of cancer, tissue changes spread throughout the organ due to common environmental insult and genetic composition. These changes are identified by the backscatter of light from the tissue. The first application for CRC screening identifies advanced adenomas (AA) in colorectal mucosa, from which ~90% of CRC originates. The InPoint? System measures changes at a specific area (distal rectum) that are indicative of the entire organ examined (colon).

网站

https://www.abo.health

Avivo BioOptics的外部链接

所属行业

医疗设备制造业

规模

2-10 人

总部

Chicago，IL

类型

私人持股

创立

2020

领域

Biotechnology、Cancer Screening、Nanotechnology、Optical Biopsy、Medical Product、Diagnostic和Risk Stratification